NasdaqCM:CAPRBiotechs
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review
Capricor Therapeutics (CAPR) is back in focus after announcing that Phase 3 HOPE-3 results for its Duchenne muscular dystrophy therapy Deramiocel will feature in a late breaking oral session and now support an active FDA review.
See our latest analysis for Capricor Therapeutics.
The HOPE-3 update lands after a period of intense momentum, with a 20.03% 1 month share price return, a very large 90 day share price gain and a 463.62% 3 year total shareholder return, all pointing to expectations...